Systemic delivery of a high-capacity adenoviral vector expressing mouse CTLA4lg improves skeletal muscle gene therapy

Molecular Therapy

Volumn 6, Issue 3, 2002, Pages 369-376

  Jiang, Zhilong ^a   Feingold, Eleanor ^b   Kochanek, Stefan ^c   Clemens, Paula R ^a,b,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF COLOGNE   (Germany)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adenoviridae; Gene therapy; Immunity; Immunosuppression; Skeletal muscle

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; INTERLEUKIN 2; INTERLEUKIN 4; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ADMINISTRATION ROUTE; FOOT PAD; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INHIBITION KINETICS; LYMPHOCYTIC INFILTRATION; MOUSE; MUSCLE DISEASE; NONHUMAN; PROTEIN EXPRESSION; SKELETAL MUSCLE; SPLEEN CELL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TRANSGENE; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALIA;

EID: 0345829919     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2002.0676     Document Type: Article

References (29)

1. Yuasa, K., et al. (1998). Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of truncated dystrophin cDNAs. FEBS Lett. 425: 329-336.
2. Wang, B., Li, J., and Xiao, X. (2000). Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl. Acad. Sci. USA 97: 13714-13719.
3. Clemens, P. R., et al. (1996). In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther. 3: 965-972.
4. Lochmuller, H., et al. (1996). Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. Gene Ther. 3: 706-716.
5. Ragot, T., et al. (1993). Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature 361: 647-650.
6. Vincent, N., et al. (1993). Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene. Nat. Genet. 5: 130-134.
7. Guibinga, G. H., et al. (1998). Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles. J. Virol. 72: 4601-4609.
8. Jiang, Z. L., et al. (2001). Local high-capacity adenovirus-mediated mCTLA4Ig and mCD40Ig expression prolongs recombinant gene expression in skeletal muscle. Mol. Ther. 3: 892-900, doi:10.1006/mthe.2001.0331.
9. Kita, Y., et al. (1999). Prolonged cardiac allograft survival in rats systemically injected adenoviral vectors containing CTLA4Ig-gene. Transplantation 68: 758-766.
10. Kay, M. A., et al. (1997). Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc. Natl. Acad. Sci. USA 94: 4686-4691.
11. Wilson, C. B., et al. (1998). Transient inhibition of CD28 and CD40 ligand interactions prolongs adenovirus-mediated transgene expression in the lung and facilitates expression after secondary vector administration. J. Virol. 72: 7542-7550.
12. Ijima, K., et al. (2001). Successful gene therapy via intraarticular injection of adenovirus vector containing CTLA4IgG in a murine model of type II collagen-induced arthritis. Hum. Gene Ther. 12: 1063-1077.
13. Takehara, M., et al. (2001). Long-term acceptance of allografts by in vivo gene transfer of regulatable adenovirus vector containing CTLA4IgG and IoxP. Hum. Gene Ther. 12: 415-426.
14. Guillot, C., et al. (2000). Tolerance to cardiac allografts via local and systemic mechanisms after adenovirus-mediated CTLA4Ig expression. J. Immunol. 164: 5258-5268.
15. Lores, B., Garcia-Estevez, J. M., and Arias, C. (1998). Lymph nodes and human tumors. Int. J. Mol. Med. 1: 729-733.
16. Labow, D., Lee, S., Ginsberg, R. J., Crystal, R. G., and Korst, R. J. (2000). Adenovirus vector-mediated gene transfer to regional lymph nodes. Hum. Gene Ther. 11: 759-769.
17. Korst, R. J., et al. (2001). Adenovirus gene transfer vectors inhibit growth of lymphatic tumor metastases independent of a therapeutic transgene. Hum. Gene Ther. 12: 1639-1649.
18. Walunas, T. L., Bakker, C. Y., and Bluestone, J. A. (1996). CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183: 2541-2550.
19. Krummel, M. F., and Allison, J. P. (1996). CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183: 2533-2540.
20. Ohba, M., et al. (2001). Long-term graft acceptance in rat heart transplantation by CTLA4Ig gene transfection combined with FTY720 treatment. World J. Surg. 25: 391-397.
21. Ugurlu, M. M., et al. (2001). The effects of CTLA-4Ig on acute lung allograft rejection: a comparison of intrabronchial gene therapy with systemic administration of protein. Transplantation 71: 1867-1871.
22. Chen, H. H., et al. (1999). DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle. Hum. Gene Ther. 10: 365-373.
23. Ritter, T., et al. (2000). Stimulatory and inhibitory action of cytokines on the regulation of hCMV-IE promoter activity in human endothelial cells. Cytokine 12: 1163-1170.
24. Hartigan-O'Connor, D., Kirk, C. J., Crawford, R., Mule, J. J., and Chamberlain, J. S. (2001). Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol. Ther. 4: 525-533, doi:10.1006/mthe.2001.0496.
25. Arahata, K., and Engel, A. G. (1988). Monoclonal antibody analysis of mononuclear cells in myopathies. i.v.: Cell-mediated cytotoxicity and muscle fiber necrosis. Ann. Neurol. 23: 168-173.
26. Engel, A. G., and Arahata, K. (1986). Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum. Pathol. 17: 704-721.
27. Spencer, M. J., Walsh, C. M., Dorshkind, K. A., Rodriguez, E. M., and Tidball, J. G. (1997). Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity. J. Clin. Invest. 99: 2745-2751.
28. Hohlfeld, R., Engel, A. G., Goebels, N., and Behrens, L. (1997). Cellular immune mechanisms in inflammatory myopathies. Curr. Opin. Rheumatol. 9: 520-526.
29. Hohlfeld, R., and Engel, A. G. (1994). The immunobiology of muscle. Immunol. Today 15: 269-274.